VANDA PHARMACEUTICALS INC(NASDAQ:VNDA) stock News

VNDA Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Monumental Sports & Entertainment

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

18 days ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

19 days ago - By: Benzinga - Mentions: GSK ANAB

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

25 days ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

2 months ago - By: Stocktwits - Mentions: IWMW AVUS

Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark

3 months ago - By: Benzinga - Mentions: BSAC BGC RMNI MTZ ...

Earnings Scheduled For July 31, 2025

2 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

2 months ago - By: Stocktwits

Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals”

2 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

2 months ago - By: Vanda Pharmaceuticals Inc.

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

3 months ago - By: The Motley Fool

Vanda (VNDA) Q2 Revenue Rises 4%

3 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

5 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

5 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

6 months ago - By: Zacks Investment Research - Mentions: PRME

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

6 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

6 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

6 months ago - By: Zacks Investment Research - Mentions: TARS

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: Vanda Pharmaceuticals Inc.

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

7 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

7 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

8 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

9 months ago - By: Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

9 months ago - By: AnaptysBio, Inc. - Mentions: ANAB

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

9 months ago - By: Vanda Pharmaceuticals Inc. - Mentions: ANAB

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

9 months ago - By: Vanda Pharmaceuticals Inc.

VANDA PHARMACEUTICALS INC (VNDA) Stock News

VNDA Latest News, Press Relases and Analysis

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark

Earnings Scheduled For July 31, 2025

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals”

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda (VNDA) Q2 Revenue Rises 4%

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis